The mechanisms behind tumor-reactive CD8+ T cell dysfunction have been studied since the defining in 1968 of the Hellström paradox - the highly immunosuppressive tumor microenvironment (TME) must be overcome for effective immunotherapy4. This evidence concerns the gene CD8A and neoplasm.